Document is current

Article History

Received: 18 January 2023

Accepted: 31 May 2023

First Online: 9 June 2023

Declarations

:

: This study complied with ethics requirements as specified by the Independent Ethics Committee/Institutional Review board and by local regulations in each country. Each participant signed a participation agreement/informed consent form in line with local regulations and trial sponsor policy, before data collection.

: Not applicable.

: LG has received grants or contracts from Pfizer, Sandoz and UCB, consulting fees from AbbVie, Bristol-Myers Squibb, Celltrion, Galapagos, Janssen, Novartis, Pfizer and UCB, honoraria for lectures from AbbVie, Amgen, Galapagos, Gilead, Janssen, Lilly, MSD, Pfizer, Sandoz and UCB, support for attending meetings and/or travel from AbbVie, Janssen, Novartis, Pfizer and UCB, and has participated on a data safety monitoring board or advisory board for and has received medical writing support from Janssen, Pfizer and UCB. PB is a shareholder of Johnson & Johnson. SDC, FL and WN are employees of Janssen and shareholders of Johnson & Johnson. MS is an employee of Janssen. ET and PB were employees of Janssen when the study was initiated. JSS has been part of speakers’ bureaus for AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Gilead, ILTOO, Janssen, Lilly, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi and UCB, and has received consulting fees from AbbVie, AstraZeneca, Lilly, Novartis and Roche. SS has received grants or contracts from Amgen (previously Celgene), Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, GSK, Janssen and UCB, consulting fees from AbbVie, Eli Lilly, Janssen and UCB, payment or honoraria for lectures etc. from AbbVie, Biogen, GSK, Janssen, Novartis and UCB, and support for attending meetings and/or travel from AbbVie, Janssen and UCB.